What is the therapeutic effect of teritusumab? What improvements can be expected after treatment?

Teritolumab (Teclistamab) is a novel bispecific antibody designed to treat multiple myeloma (MM). Its mechanism of action is to activate T cells and guide them to attack tumor cells expressing BCMA by simultaneously binding CD3 and BCMA (B cell maturation antigen) molecules. BCMA is an important target on the surface of multiple myeloma cells. Teritolumab can effectively target these cancer cells and promote an effective response of the immune system, thereby inhibiting tumor growth.

Teritusumab has demonstrated significant clinical efficacy in the treatment of multiple myeloma. Multiple clinical studies have shown that among patients treated with teritusumab, many experienced disease responses, including complete and partial responses. Its efficacy is particularly outstanding in patients with relapsed and refractory multiple myeloma who are refractory to conventional treatments. Patients' quality of life also improved significantly, with many reporting pain relief and functional recovery.

After treatment, teritusumab can significantly prolong the progression-free survival (PFS) and overall survival (OS) of patients. By targeting BCMA, it can effectively inhibit the proliferation and spread of tumor cells and reduce tumor burden during treatment. This is particularly important for patients with a history of multiple chemotherapy treatments or drug resistance, for whom teritolumab provides a new treatment option.

However, despite its significant advantages in efficacy, its side effects are also an aspect that needs attention during treatment. Common adverse reactions include cytokine release syndrome (CRS) and neurological-related side effects, especially in the early stages of treatment. When patients receive teritusumab treatment, they need to be closely monitored and receive necessary supportive treatment to ensure the safety and effectiveness of the drug. Overall, teritusumab brings new hope for the treatment of multiple myeloma, especially for patients who have failed to respond to traditional treatments.

Reference materials:https://www.tecvayli.com/